What Does Today's Pop Mean for Vertex?

On Tuesday's MarketFoolery, host Mark Reeth, along with Million Dollar Portfolio analyst Michael Olsen, and Motley Fool One analyst Morgan Housel, discuss Vertex's recent jump.

After two cystic fibrosis trials finished with strong results, Vertex's stock jumped over 40% today. Mark wonders what the pop means for Vertex and whether the stock can move even further. Michael explains that the drugs are considered "orphan drugs," as they currently don't have any competition and are specialized. Furthermore, he notes that the drugs basically have a license to price. For this particular market, Michael suggests that investors have to be part scientists and part investors, because of the challenges associated with drug trials. Morgan offers that the large market move indicates that expectations about the trial's results were unknown. Both Morgan and Michael agree that investing in these smaller biotech companies can be difficult and feel a bit like gambling.

Invest with confidence with this biotech report
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. To that end, there is a product in development that will change how we treat a common chronic illness and also potentially revolutionize the entire health industry. Analysts are already licking their chops at the sales potential. To outsmart Wall Street and realize multibagger returns, you need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. Click here now.

The article What Does Today's Pop Mean for Vertex? originally appeared on Fool.com.

Mark Reeth, Michael Olsen, CFA, and Morgan Housel have no position in any stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story